Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia.
Saved in:
| Title: | Cladribine, high-dose cytarabine, plus gemtuzumab ozogamicin (CLAG-GO) as frontline intensive therapy for fit patients with core-binding factor acute myeloid leukemia. |
|---|---|
| Authors: | Azevedo, Roberta S.1 (AUTHOR), Braish, Julie1 (AUTHOR), Gener-Ricos, Georgina1 (AUTHOR), Tang, Guilin2 (AUTHOR), Sasaki, Koji1 (AUTHOR), Montalban-Bravo, Guillermo1 (AUTHOR), Jabbour, Elias1 (AUTHOR), Ohanian, Maro1 (AUTHOR), Yilmaz, Musa1 (AUTHOR), Haddad, Fadi G.1 (AUTHOR), Chien, Kelly1 (AUTHOR), Ishizawa, Jo1 (AUTHOR), Short, Nicholas J.1 (AUTHOR), Maiti, Abhishek1 (AUTHOR), Swaminathan, Mahesh1 (AUTHOR), Kantarjian, Hagop1 (AUTHOR), Borthakur, Gautam1 (AUTHOR), Kadia, Tapan M.1 (AUTHOR) tkadia@mdanderson.org |
| Source: | Leukemia & Lymphoma. Jan2026, Vol. 67 Issue 1, p220-224. 5p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
